BAD THINGS: Stated in the 10-Q, it says that there has been a big push to develop a seed that does not require surgery to implant or take out. Therma-seed, the product TGX currently sells and markets, requires surgery to implant and remove.
Buyers of TGX's product are ordering less due to uncertainty in the healthcare system and TGX is directly affected with a 2% increase in tax from the Affordable Care Act.
GOOD THINGS: Although revenue has slightly decreased, this company still generates good revenue and a positive bottom line. At the moment it is moderately undervalued.
Recent share buy-back program and new credit line show me that the company expects large growth in the future.